An overview of process development for antibody-drug conjugates produced by chemical conjugation technology

2020 ◽  
pp. 1-13
Author(s):  
Yutaka Matsuda ◽  
Brian A. Mendelsohn
Keyword(s):  
Process Development ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Chemical Conjugation ◽  
Antibody Drug

Process Development and Manufacturing of Antibody-Drug Conjugates

2018 ◽  
pp. 813-836
Author(s):  
Matt H. Hutchinson ◽  
Rachel S. Hendricks ◽  
Xin Xin Lin ◽  
Dana A. Olson
Keyword(s):  
Process Development ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Antibody Drug

Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation

2020 ◽  
Vol 1140 ◽  
pp. 121981 ◽  
Author(s):  
Yutaka Matsuda ◽  
Maria-Christina Malinao ◽  
Veronica Robles ◽  
James Song ◽  
Kei Yamada ◽  
...  
Keyword(s):  
First Generation ◽  
Site Specificity ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Chemical Conjugation ◽  
Antibody Drug

scholarly journals Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody–drug conjugates

2021 ◽  
Author(s):  
Min Sun Kang ◽  
Theresa Wai See Kong ◽  
Joycelyn Yi Xin Khoo ◽  
Teck-Peng Loh
Keyword(s):  
Amino Acids ◽  
Chemical Modification ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Chemical Conjugation ◽  
Recent Developments ◽  
Antibody Drug

The review shall introduce and analyse the current developments in the chemical modification of native amino acids on peptides or proteins and their applicability to ADC linkers.

ASCO-GU 2019: Metastasierte Urothelkarzinome

2019 ◽  
Vol 10 (03) ◽  
pp. 140-141
Author(s):  
Alexander Kretzschmar
Keyword(s):  
San Francisco ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Chapel Hill ◽  
Antibody Drug

Die Therapielandschaft des metastasierten Urothelkarzinoms hat sich seit der Zulassung der ersten Immun-Checkpoint-Inhibitoren verändert. Die neuen Therapien sind deutlich effektiver, allerdings erreichen die Responseraten der neuen Therapien nur bis zu etwa 30 %, beklagte Prof. Matthew Milowsky, Chapel Hill/USA, auf einer Oral Abstract Session auf dem ASCO-GU. In San Francisco gaben erste Vorträge und Poster bereits einen Einblick, wovon diejenigen Patienten profitieren könnten, die auf die etablierten Chemotherapien und die neuen Immuntherapien nicht ansprechen. Manche Onkologen sprechen bereits von der „Post-Checkpoint-Ära”. Als Kandidaten werden vor allem Antikörper-Wirkstoff-Konjugate (antibody-drug conjugates; ADC) gehandelt – und zwar nicht nur zur Therapie des metastasierten Blasenkarzinoms.

scholarly journals Application of triple quadrupole mass spectrometry for the characterization of antibody–drug conjugates

2019 ◽  
Vol 411 (12) ◽  
pp. 2569-2576 ◽  
Author(s):  
Malin Källsten ◽  
Matthijs Pijnappel ◽  
Rafael Hartmann ◽  
Fredrik Lehmann ◽  
Lucia Kovac ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Triple Quadrupole ◽  
Quadrupole Mass ◽  
Triple Quadrupole Mass Spectrometry ◽  
Antibody Drug Conjugates ◽  
Quadrupole Mass Spectrometry ◽  
Drug Conjugates ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document